G23.1 G23.2 G23.3
Conditions
Interventions
Group 1: Assessment of disease history, course, genetics and pathophysiology of neurodegenerative diseases.
Use of clinical and psychiatric scales, collection of biomaterial (blood and urine), analys
Sponsors
Klinikum rechts der Isar der TU München
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) The presence of a clinical diagnosis of PSP or 4-repeat tauopathy according to the valid diagnostic criteria (Höglinger et al., 2017). 2) The presence of a clinical diagnosis of MSA according to the valid diagnostic criteria (Wenning et al., 2022 and Gilman et al., 2008) 3) Persons at risk of developing MSA. These include subjects with idiopathic RBD (Sateia, 2014) and Pure Autonomic Failure (PAF, Fanciulli & Wenning, 2015). These are defined according to the corresponding items of the clinical MSA criteria for possible MSA. In the diagnostic criteria of idiopathic RBD, the following symptoms are obligatory: - repeated episodes of arousal during sleep associated with vocalization and / or complex movements - the behavior occurs during REM sleep and - upon awakening from these episodes completely awake, alert and not confused or disoriented. In addition, one of the following criteria is present in RBD: - on polysomnography, REM sleep without atonia (RSWA), - history suggests REM sleep behavior disorder and a synucleinopathy diagnosis, - the behavior causes clinically significant impairment in social, occupational, or other major life functions (including self-injury or injury to others), - the disorder is not due to the physiological effects of a substance, and - coexisting mental and medical disorders cannot explain the occurrence of the episodes.
Exclusion criteria
Exclusion criteria: The exclusion criteria correspond to the MDS-PSP diagnostic criteria as well as the Gilman MSA diagnostic criteria and the MDS-MSA diagnostic criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of this study is to set up a clinical register to study natural history, disease course, genetics and pathophysiology of atypical parkinson syndroms. In the long term, analysis of the data collected should improve early diagnosis and prediction of disease progression. | — |
Secondary
| Measure | Time frame |
|---|---|
| A secondary endpoint of the ProAPS study is to build a trial-ready cohort. | — |
Countries
Austria, Germany, Spain
Contacts
Public ContactGünter Höglinger
Klinikum der Universität München A.ö.R.
Outcome results
None listed